Kura Oncology Enters Material Definitive Agreement
Ticker: KURA · Form: 8-K · Filed: Nov 20, 2024 · CIK: 1422143
| Field | Detail |
|---|---|
| Company | Kura Oncology, INC. (KURA) |
| Form Type | 8-K |
| Filed Date | Nov 20, 2024 |
| Risk Level | medium |
| Pages | 7 |
| Reading Time | 8 min |
| Key Dollar Amounts | $0.0001, $330 million, $420 million, $513 million, $228 million |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-definitive-agreement, 8-k
TL;DR
Kura Oncology just signed a big deal, filing an 8-K to let everyone know.
AI Summary
On November 20, 2024, Kura Oncology, Inc. entered into a material definitive agreement. The company, incorporated in Delaware with its principal executive offices in San Diego, CA, filed this 8-K report to disclose this significant event.
Why It Matters
This filing indicates a significant development for Kura Oncology, potentially impacting its business operations, strategic direction, or financial standing.
Risk Assessment
Risk Level: medium — Entering into a material definitive agreement can introduce new risks or opportunities that may affect the company's future performance.
Key Numbers
- 001-37620 — Commission File Number (Identifies the company's SEC filings)
- 61-1547851 — IRS Employer Identification No. (Company's tax identification number)
Key Players & Entities
- Kura Oncology, Inc. (company) — Registrant
- November 20, 2024 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- San Diego, CA (location) — Address of Principal Executive Offices
- ZETA ACQUISITION CORP III (company) — Former Company Name
FAQ
What is the nature of the material definitive agreement entered into by Kura Oncology, Inc.?
The filing does not specify the nature of the material definitive agreement, only that one was entered into on November 20, 2024.
When was this material definitive agreement reported?
The material definitive agreement was reported on November 20, 2024.
What is Kura Oncology, Inc.'s state of incorporation?
Kura Oncology, Inc. is incorporated in Delaware.
What is the address of Kura Oncology, Inc.'s principal executive offices?
The address of Kura Oncology, Inc.'s principal executive offices is 12730 High Bluff Drive, Suite 400, San Diego, CA 92130.
Was Kura Oncology, Inc. previously known by another name?
Yes, Kura Oncology, Inc. was formerly known as ZETA ACQUISITION CORP III.
Filing Stats: 2,009 words · 8 min read · ~7 pages · Grade level 17.2 · Accepted 2024-11-20 17:21:01
Key Financial Figures
- $0.0001 — ich registered Common Stock, par value $0.0001 per share KURA The Nasdaq Global Se
- $330 million — pany will receive an upfront payment of $330 million and is eligible to receive up to $420 m
- $420 million — illion and is eligible to receive up to $420 million in near-term milestone payments, includ
- $513 million — ry and commercial milestone payments of $513 million for the existing Field (i.e., hematolog
- $228 million — upfront and milestone payments totaling $228 million for the expanded Field, totaling up to
- $1.491 billion — for the expanded Field, totaling up to $1.491 billion in upfront and milestone payments in th
Filing Documents
- d902118d8k.htm (8-K) — 34KB
- 0001193125-24-262641.txt ( ) — 157KB
- kura-20241120.xsd (EX-101.SCH) — 3KB
- kura-20241120_lab.xml (EX-101.LAB) — 18KB
- kura-20241120_pre.xml (EX-101.PRE) — 11KB
- d902118d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, including without limitation statements regarding the Company's receipt of an upfront payment and potential receipt of an additional upfront payment, milestone payments and tiered double-digit royalties under the Agreement, Kyowa Kirin's option under the Agreement and potential exercise thereof, the development plan under the Agreement and potential regulatory approval of ziftomenib in the United States. The words "anticipate," "believe," "continue," "could," "estimate," "expect," "intend," "may," "plan," "potential," "predict," "project," "target," "should," "would," and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements as a result of various important factors, including risks relating to the success of the collaboration and development of ziftomenib under the collaboration, Kyowa Kirin's willingness to exercise its option, risks and uncertainties associated with the Company's business and finances in general, and risks described under the caption "Risk Factors" in the Company's Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2024, which is on file with the SEC; and risks described in other filings that the Company makes with the SEC in the future. Any forward-looking statements contained in this Current Report on Form 8-K speak only as of the date hereof, and the Company expressly disclaims any obligation to update any forward-looking statements, whether because of new information, future events or otherwise.
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: November 20, 2024 KURA ONCOLOGY, INC. By: /s/ Teresa Bair Teresa Bair Chief Legal Officer